SLC5A2 and kidney disorder: What is the effect of SGLT2 inhibitors on cardiovascular death, hospitalization for heart failure, exercise capacity, symptoms (as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)), kidney disease progression, and other renal outcomes in HFpEF?